Indolinone-based acetylcholinesterase inhibitors: Synthesis, biological activity and molecular modeling

European Journal of Medicinal Chemistry

Volumn 84, Issue , 2014, Pages 375-381

  Akrami, Hamidreza ^a   Mirjalili, Bibi Fatemeh ^a   Khoobi, Mehdi ^b   Nadri, Hamid ^c   Moradi, Alireza ^c   Sakhteman, Amirhossein ^c   Emami, Saeed ^d   Foroumadi, Alireza ^b   Shafiee, Abbas ^b  

^a YAZD UNIVERSITY   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c SHAHID SADOUGHI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d MAZANDARAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Acetylcholinesterase; Alzheimer's disease; Docking study; Indolinone; Oxindole

Indexed keywords

1 (2 BROMOBENZYL) 4 ((2 OXOINDOLIN 3 YLIDENE)METHYL) PYRIDINIUM CHLORIDE; 1 (2 CHLORO 6 FLUOROBENZYL) 4 ((2 OXOINDOLIN 3 YLIDENE)METHYL)PYRIDINIUM CHLORIDE; 1 (2 CHLOROBENZYL) 4 ((2 OXOINDOLIN 3 YLIDENE)METHYL) PYRIDINIUM CHLORIDE; 1 (2 FLUOROBENZYL) 4 ((2 OXOINDOLIN 3 YLIDENE)METHYL) PYRIDINIUM CHLORIDE; 1 (2 METHYLBENZYL) 4 ((2 OXOINDOLIN 3 YLIDENE)METHYL) PYRIDINIUM CHLORIDE; 1 (2 NITROBENZYL) 4 ((2 OXOINDOLIN 3 YLIDENE)METHYL) PYRIDINIUM BROMIDE; 1 (2,6 DICHLOROBENZYL) 4 ((2 OXOINDOLIN 3 YLIDENE)METHYL)PYRIDINIUM CHLORIDE; 1 (3 BROMOBENZYL) 4 ((2 OXOINDOLIN 3 YLIDENE)METHYL)PYRIDINIUM CHLORIDE; 1 (3 CHLOROBENZYL) 4 ((2 OXOINDOLIN 3 YLIDENE)METHYL) PYRIDINIUM BROMIDE; 1 (3 FLUOROBENZYL) 4 ((2 OXOINDOLIN 3 YLIDENE)METHYL)PYRIDINIUM CHLORIDE; 1 (3 METHOXYLBENZYL) 4 ((2 OXOINDOLIN 3 YLIDENE)METHYL)PYRIDINIUM CHLORIDE; 1 (3 METHYLBENZYL) 4 ((2 OXOINDOLIN 3 YLIDENE)METHYL)PYRIDINIUM CHLORIDE; 1 (4 BROMOBENZYL) 4 ((2 OXOINDOLIN 3 YLIDENE)METHYL)PYRIDINIUM CHLORIDE; 1 (4 CHLOROBENZYL) 4 ((2 OXOINDOLIN 3 YLIDENE)METHYL)PYRIDINIUM CHLORIDE; 1 (4 FLUOROBENZYL) 4 ((2 OXOINDOLIN 3 YLIDENE)METHYL)PYRIDINIUM CHLORIDE; 1 (4 METHOXYBENZYL) 4 ((2 OXOINDOLIN 3 YLIDENE)METHYL)PYRIDINIUM CHLORIDE; 1 (4 NITROBENZYL) 4 ((2 OXOINDOLIN 3 YLIDENE)METHYL)PYRIDINIUM CHLORIDE; 1 (BENZYL) 4 ((2 OXOINDOLIN 3 YLIDENE)METHYL)PYRIDINIUM BROMIDE; 3 (PYRIDIN 4 YLMETHYLENE)INDOLIN 2 ONE; ACETYLCHOLINESTERASE; BENZYL DERIVATIVE; CHOLINESTERASE; CHOLINESTERASE INHIBITOR; DONEPEZIL; INDOLE DERIVATIVE; OXINDOLE; PYRIDIN 4 CARBALEHYDE; PYRIDINE DERIVATIVE; PYRIDINIUM DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; 1 (2 BROMOBENZYL) 4 [(2 OXOINDOLIN 3 YLIDENE)METHYL]PYRIDINIUM CHLORIDE; 1 (2 CHLORO 6 FLUOROBENZYL) 4 [(2 OXOINDOLIN 3 YLIDENE)METHYL]PYRIDINIUM CHLORIDE; 1 (2 CHLOROBENZYL) 4 [(2 OXOINDOLIN 3 YLIDENE)METHYL]PYRIDINIUM CHLORIDE; 1 (2 FLUOROBENZYL) 4 [(2 OXOINDOLIN 3 YLIDENE)METHYL]PYRIDINIUM CHLORIDE; 1 (2 METHYLBENZYL) 4 [(2 OXOINDOLIN 3 YLIDENE)METHYL]PYRIDINIUM CHLORIDE; 1 (2 NITROBENZYL) 4 [(2 OXOINDOLIN 3 YLIDENE)METHYL]PYRIDINIUM BROMIDE; 1 (2,4 DICHLOROBENZYL) 4 [(2 OXOINDOLIN 3 YLIDENE)METHYL]PYRIDINIUM CHLORIDE; 1 (2,6 DICHLOROBENZYL) 4 [(2 OXOINDOLIN 3 YLIDENE)METHYL]PYRIDINIUM CHLORIDE; 1 (3 BROMOBENZYL) 4 [(2 OXOINDOLIN 3 YLIDENE)METHYL]PYRIDINIUM CHLORIDE; 1 (3 CHLOROBENZYL) 4 [(2 OXOINDOLIN 3 YLIDENE)METHYL]PYRIDINIUM BROMIDE; 1 (3 FLUOROBENZYL) 4 [(2 OXOINDOLIN 3 YLIDENE)METHYL]PYRIDINIUM CHLORIDE; 1 (3 METHOXYBENZYL) 4 [(2 OXOINDOLIN 3 YLIDENE)METHYL]PYRIDINIUM CHLORIDE; 1 (3 METHYLBENZYL) 4 [(2 OXOINDOLIN 3 YLIDENE)METHYL]PYRIDINIUM CHLORIDE; 1 (3,4 DICHLOROBENZYL) 4 [(2 OXOINDOLIN 3 YLIDENE)METHYL]PYRIDINIUM CHLORIDE; 1 (4 BROMOBENZYL) 4 [(2 OXOINDOLIN 3 YLIDENE)METHYL]PYRIDINIUM CHLORIDE; 1 (4 CHLOROBENZYL) 4 [(2 OXOINDOLIN 3 YLIDENE)METHYL]PYRIDINIUM CHLORIDE; 1 (4 CHLOROMETHYLBENZYL) 4 [(2 OXOINDOLIN 3 YLIDENE)METHYL]PYRIDINIUM CHLORIDE; 1 (4 FLUOROBENZYL) 4 [(2 OXOINDOLIN 3 YLIDENE)METHYL]PYRIDINIUM CHLORIDE; 1 (4 METHOXYBENZYL) 4 [(2 OXOINDOLIN 3 YLIDENE)METHYL]PYRIDINIUM CHLORIDE; 1 (4 NITROBENZYL) 4 [(2 OXOINDOLIN 3 YLIDENE)METHYL]PYRIDINIUM CHLORIDE; 1 (BENZYL) 4 [(2 OXOINDOLIN 3 YLIDENE)METHYL]PYRIDINIUM BROMIDE; INDOLINONE;

ARTICLE; BENZYLATION; BINDING SITE; BIOLOGICAL ACTIVITY; BLOOD BRAIN BARRIER; CATALYTIC ANIONIC SITE; CHEMISTRY; CHOLINESTERASE INHIBITION; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG METABOLISM; DRUG PENETRATION; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; IC 50; IN VITRO STUDY; MOLECULAR DOCKING; MOLECULAR MODEL; N BENZYLATION; PERIPHERAL ANIONIC SITE; IC50; CHEMICAL STRUCTURE; DOSE RESPONSE; METABOLISM; STRUCTURE ACTIVITY RELATION; SYNTHESIS;

ACETYLCHOLINESTERASE; BUTYRYLCHOLINESTERASE; CHOLINESTERASE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; INDOLES; MODELS, MOLECULAR; MOLECULAR STRUCTURE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84904560630     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2014.01.017     Document Type: Article

References (31)

1. Alzheimer's Disease International World Alzheimer Report 2011 1
2. C. Ballard, S. Gauthier, A. Corbett, C. Brayne, D. Aarsland, and E. Jones Lancet 377 2011 1019 1031
3. M. Weinstock J. Neural Transm. 49 1997 93 102
4. C.G. Ballard, N.H. Greig, A.L. Guillozet-Bongaarts, A. Enz, and S. Darvesh Curr. Alzheimer Res. 2 2005 307 318
5. E. Scarpini, P. Scheltens, and H. Feldman Lancet Neurol. 2 2003 539 547
6. B.M. McGleenon, K.B. Dynan, and A.P. Passmore Br. J. Clin. Pharmacol. 48 1999 471 480
7. A. Lleo, S.M. Greenberg, and J.H. Growdon Annu. Rev. Med. 57 2006 513 533
8. L.L. Shen, G.X. Liu, and Y. Tang Acta Pharmacol. Sin. 28 2007 2053 2063
9. J. Marco-Contelles, M.D. Carreiras, C. Rodriguez, M. Villarroya, and A.G. Garcia Chem. Rev. 106 2006 116 133
10. J.L. Sussman, M. Harel, F. Frolow, C. Oefner, A. Goldman, L. Toker, and I. Silman Science 253 1991 872 879
11. M. Pera, A. Martinez-Otero, L. Colombo, M. Salmona, D. Ruiz-Molina, and A. Badia et al. Mol. Cell. Neurosci. 40 2009 217 224
12. E. Giacobini Neurochem. Res. 28 2003 515 522
13. G. Koellner, G. Kryger, C.B. Millard, I. Silman, J.L. Sussman, and T. Steiner J. Mol. Biol. 296 2000 713 735
14. A. Saxena, J.M. Fedorko, C.R. Vinayaka, R. Medhekar, Z. Radić, P. Taylor, O. Lockridge, and B.P. Doctor Eur. J. Biochem. 270 2003 4447 4458
15. R. León, A.G. Garcia, and J. Marco-Contelles Med. Res. Rev. 33 2013 139 189
16. W. Tong, E.R. Collantes, Y. Chen, and W.J. Welsh J. Med. Chem. 39 1996 380 387
17. J.Q. Araújo, M.A. de Brito, L.V. Hoelz, R.B. de Alencastro, H.C. Castro, C.R. Rodrigues, and M.G. Albuquerque Eur. J. Med. Chem. 46 2011 39 51
18. H. Nadri, M. Pirali-Hamedani, M. Shekarchi, M. Abdollahi, V. Sheibani, M. Amanlou, A. Shafiee, and A. Foroumadi Bioorg. Med. Chem. 18 2010 6360 6366
19. M. Alipour, M. Khoobi, A. Foroumadi, H. Nadri, A. Moradi, and A. Sakhteman et al. Bioorg. Med. Chem. 20 2012 7214 7222
20. M. Alipour, M. Khoobi, H. Nadri, A. Sakhteman, A. Moradi, and M. Ghandi et al. Arch. Pharm. Chem. Life Sci. 346 2013 577 587
21. S.F. Razavi, M. Khoobi, H. Nadri, and A. Sakhteman et al. Eur. J. Med. Chem. 64 2013 252 259
22. M. Khoobi, M. Alipour, A. Moradi, A. Sakhteman, and H. Nadri et al. Eur. J. Med. Chem. 68 2013 291 300
23. M. Khoobi, M. Alipour, A. Sakhteman, H. Nadri, and A. Moradi et al. Eur. J. Med. Chem. 68 2013 260 269
24. N. Hosseinzadeh, M. Hasani, A. Foroumadi, H. Nadri, S. Emami, N. Samadi, M.A. Faramarzi, P. Saniee, F. Siavoshi, N. Abadian, Y. Mahmoudjanlou, A. Sakhteman, A. Moradi, and A. Shafiee Med. Chem. Res. 22 2013 2293 2302
25. A. Andreani, S. Burnelli, M. Granaiola, A. Leoni, A. Locatelli, R. Morigi, M. Rambaldi, L. Varoli, L. Landi, C. Prata, F. Vieceli Dalla Sega, C. Caliceti, and R.H. Shoemaker Bioorg. Med. Chem. 18 2010 3004 3011
26. F. Cheng, W. Li, Y. Zhou, J. Shen, Z. Wu, G. Liu, P.W. Lee, and Y. Tang J. Chem. Inf. Model. 52 2012 3099 3105
27. G.L. Ellman, K.D. Courtney, V. Andres, and R.M. Featherstone Biochem. Pharmacol. 7 1961 88 95
28. M.F. Sanner J. Mol. Graph. Model. 17 1999 57 61
29. N.M. O'Boyle, M. Banck, C.A. James, C. Morley, T. Vandermeersch, and G.R. Hutchison J. Cheminf. 3 2011 33
30. O. Trott, and A.J. Olson J. Comput. Chem. 31 2010 455 461
31. E.F. Pettersen, T.D. Goddard, C.C. Huang, G.S. Couch, D.M. Greenblatt, E.C. Meng, and T.E. Ferrin J. Comput. Chem. 25 2004 1605 1612